Company intelligence / Profile preview

Cyprium Therapeutics, Inc.

New York, New York, United Statescypriumtx.com ↗

Ownership: Private
Development stage: NDA

Overview

Cyprium's lead product CUTX-101 (Copper Histidinate injection) has shown positive results in pivotal studies with a nearly 80% reduction in risk of death compared to historical controls. The NDA has been granted Priority Review by the FDA with a PDUFA date of September 30, 2025.

Therapeutic areas: Rare DiseasesMetabolic Disorders
Modalities: Small moleculesGene therapy
Industry: Biotech

Drug pipeline

2 assets

copper histidine

Approved

1 more asset in the full pipeline.

Request access →

Partnerships

Sentynl Therapeutics, Inc. (Zydus Group)Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)National Institute of Neurological Disorders and Stroke (NINDS)

Beyond the preview

Go deeper on Cyprium Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyprium Therapeutics, Inc..

Explore the full profile